Parents Turn to Wegovy for Elementary School Kids

Amid growing awareness of the serious health risks tied to childhood obesity, doctors and parents are turning to Wegovy (semaglutide) for elementary school children, according to a report from The Wall Street Journal.

Details of Use

Wegovy, manufactured by Novo Nordisk, is FDA-approved for obesity in adults and adolescents aged 12 and older. However, the report indicates that some physicians are prescribing it off-label for younger children, raising questions about safety and efficacy.

Context

This trend comes amid a rising childhood obesity crisis in the U.S., where approximately 20% of children are obese. Doctors see limited existing treatment options, prompting exploration of new approaches.

What This Means for Investors

While the report does not provide specific figures, the trend toward using weight-loss drugs in children could expand the potential market for drugs like Wegovy and its competitors, including Eli Lilly's (LLY) tirzepatide (Mounjaro/Zepbound). However, investors should monitor regulatory developments and clinical studies that may impact future approvals.